Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112
NEW YORK, Oct. 26, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, will present a poster demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. SITC is taking place November 1-5, 2023 in San Diego.
NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- The National Cancer Institute (NCI), part of the National Institutes of Health, under formal collaboration with Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, today presented preliminary results from the Phase 2 clinical trial of Promontory's lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs).
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotechnology company advancing immunogenic small molecule approaches in oncology, has become the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC), an emerging European hub for cancer research and innovation. As a member, Promontory has access to PSCC's oncology community, including experts, technology platforms, facilities and more, to support its clinical progress in Europe. Promontory's Phase 2 study of immunogenic cancer cell death inducer PT-112 was recently expanded to clinical sites in France, led by the Gustave Roussy Paris.
NEW YORK, July 20, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, has expanded its clinical presence to France. This week the company treated its first four patients in France – at Gustave Roussy and at the Military Hospital (HIA) Bégin in Paris – on the ongoing Phase 2 clinical trial of lead therapeutic candidate, PT-112, in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC) (ClinicalTrials.gov Identifier: NCT02266745).
NEW YORK, June 2, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data from a Phase 2 clinical trial of the company's lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs), specifically thymoma and thymic carcinoma. The trial is being conducted under formal collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (see NCT05104736). The data were published online in an abstract for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
NEW YORK, May 31, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will participate in a panel discussion on maximizing value in a capital efficient manner at the Sachs 9th Annual Immuno-Oncology Innovation Forum, taking place June 2, 2023 in Chicago. The company will also provide a presentation on its corporate and clinical progress with lead therapeutic candidate, PT-112, a small molecule immunotherapy.
NEW YORK, Feb. 2, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will present a poster on its clinical trial in progress of PT-112, its lead therapeutic candidate, in patients with late-stage metastatic castration-resistant prostate cancer, to be held at the American Society of Clinical Oncology 2023 Genitourinary Cancers (ASCO GU) Symposium. ASCO GU will take place in San Francisco and online on Feb. 16-18, 2023.